Conatus Pharmaceuticals to Relocate Corporate Headquarters

Conatus Pharmaceuticals to Relocate Corporate Headquarters  SAN DIEGO, July 7, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will relocate the company's corporate headquarters to a new leased facility in northern San Diego at 16745 W Bernardo Drive, Suite 200, San Diego, CA 92127. All Conatus phone numbers will change as a result of the relocation. Email addresses will not change.  Current phone numbers will remain effective until noon PDT on Thursday, July 24, 2014, when the company will close for the move. New phone numbers will be available on the company's website when the company reopens at its new location on Monday, July 28, 2014.  About Conatus Pharmaceuticals Inc.  Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing emricasan as a first-in class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease. For additional information, please visit www.conatuspharma.com.  Forward-Looking Statements  This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release, including statements regarding anticipated clinical development plans and proposed activity of emricasan in patients with liver disease, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in Conatus' prior press releases and the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in Conatus' forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Conatus does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.  CONTACT: INVESTORS          Alan Engbring, Conatus Pharmaceuticals          (858) 457-7237, aengbring@conatuspharma.com                   MEDIA          Mariesa Kemble, Sam Brown Inc.          (608) 850-4745, mariesakemble@sambrown.com  
Press spacebar to pause and continue. Press esc to stop.